Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials.

What the trial testedrandomised · 97,297 people · 2022

Randomised comparison

−40%−58% to −16%

Bigger than 8 in 10 for cardiovascular events

As reported

OR 0.60, 95% CI 0.42–0.84

Randomised comparison

−21%−34% to −5%

Bigger than 5 in 10 for cardiovascular events

As reported

OR 0.79, 95% CI 0.66–0.95

the abstract, start to end

… [OR] 0.76, 95% conﬁdence interval [CI] 0.60-0.97, p < 0.05), evolocumab (OR 0.79, 95% CI 0.66-0.95, p < 0.05) …

← favours treatmentfavours comparator →

could be chance

Cardiovascular events

OR 0.600.42–0.84

Cardiovascular events

OR 0.790.66–0.95

PCSK9 inhibitorsCardiovascular events

PCSK9 inhibitors × cardiovascular eventshelps?settled

unlikelylikely

1.00not counted

← favours treatmentfavours comparator →

more certainless certain

1 / 5

2022

2023

2024

2025

2026

this papercites it